Targeting the insulin-like growth factor-1 receptor in human cancer

Frontiers in Pharmacology

Volumn 4 MAR, Issue , 2013, Pages

  Arcaro, Alexandre ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cancer; Clinical trials; IGF 1 receptor; Insulin like growth factor; Monoclonal antibody; Tyrosine kinase inhibitor

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; 4 AMINO 5 (3 BENZYLOXYPHENYL) 7 [3 (1 PYRROLIDINYLMETHYL)CYCLOBUTYL] 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CIXUTUMUMAB; DALOTUZUMAB; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FIGITUMUMAB; GANITUMAB; GEMCITABINE; IMATINIB; LINSITINIB; MONOCLONAL ANTIBODY; NVP AEW 541; PACLITAXEL; R 1507; ROBATUMUMAB; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; AUTOCRINE EFFECT; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; COLON CANCER; COLORECTAL CANCER; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; EWING SARCOMA; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MEDULLOBLASTOMA; METASTASIS; METASTATIC COLORECTAL CANCER; MONOTHERAPY; MULTIPLE MYELOMA; NEOPLASM; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SARCOMA; SHORT SURVEY; SIGNAL TRANSDUCTION; SOLID TUMOR; TRIPLE NEGATIVE BREAST CANCER; UNSPECIFIED SIDE EFFECT;

EID: 84881523535     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00030     Document Type: Short Survey

References (79)

1. Abraham, J., Prajapati, S. I., Nishijo, K., Schaffer, B. S., Taniguchi, E., Kilcoyne, A., et al. (2011). Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. Mol. Cancer Ther. 10, 697-707.
2. Arcaro, A., Doepfner, K. T., Boller, D., Guerreiro, A. S., Shalaby, T., Jackson, S. P., et al. (2007). Novel role for insulin as an autocrine growth factor for malignant brain tumour cells. Biochem. J. 406, 57-66.
3. Atzori, F., Tabernero, J., Cervantes, A., Prudkin, L., Andreu, J., Rodriguez-Braun, E., et al. (2011). A phase I, pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-IGF-1R monoclonal antibody, in patients with advanced solid tumors. Clin. Cancer Res. 17, 6304-6312.
4. Baxter, R. C. (2000). Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am. J. Physiol. Endocrinol. Metab. 278, E967-E976.
5. Beltran, P. J., Mitchell, P., Chung, Y. A., Cajulis, E., Lu, J., Belmontes, B., et al. (2009). AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol. Cancer Ther. 8, 1095-1105.
6. Bielen, A., Perryman, L., Box, G. M., Valenti, M., De Haven Brandon, A., Martins, V., et al. (2011). Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β. Mol. Cancer Ther. 10, 1407-1418.
7. Broussas, M., Dupont, J., Gonzalez, A., Blaecke, A., Fournier, M., Corvaia, N., et al. (2009). Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor. Int. J. Cancer 124, 2281-2293.
8. Buck, E., Gokhale, P. C., Koujak, S., Brown, E., Eyzaguirre, A., Tao, N., et al. (2010). Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol. Cancer Ther. 9, 2652-2664.
9. Canzian, F., Cox, D. G., Setiawan, V. W., Stram, D. O., Ziegler, R. G., Dossus, L., et al. (2010). Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. Hum. Mol. Genet. 19, 3873-3884.
10. Cao, L., Yu, Y., Darko, I., Currier, D., Mayeenuddin, L. H., Wan, X., et al. (2008). Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res. 68, 8039-8048.
11. Carboni, J. M., Lee, A. V., Hadsell, D. L., Rowley, B. R., Lee, F. Y., Bol, D. K., et al. (2005). Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res. 65, 3781-3787.
12. Carboni, J. M., Wittman, M., Yang, Z., Lee, F., Greer, A., Hurlburt, W., et al. (2009). BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol. Cancer Ther. 8, 3341-3349.
13. Chan, J. M., Stampfer, M. J., Ma, J., Gann, P., Gaziano, J. M., Pollak, M., et al. (2002). Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J. Natl. Cancer Inst. 94, 1099-1106.
14. Chen, W., Wang, S., Tian, T., Bai, J., Hu, Z., Xu, Y., et al. (2009). Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur. J. Hum. Genet. 17, 1668-1675.
15. Cohen, B. D., Baker, D. A., Soderstrom, C., Tkalcevic, G., Rossi, A. M., Miller, P. E., et al. (2005). Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin. Cancer Res. 11, 2063-2073.
16. De Meyts, P., and Whittaker, J. (2002). Structural biology of insulin and IGF1 receptors: implications for drug design. Nat. Rev. Drug Discov. 1, 769-783.
17. Denley, A., Wallace, J. C., Cosgrove, L. J., and Forbes, B. E. (2003). The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review. Horm. Metab. Res. 35, 778-785.
18. Doepfner, K. T., Spertini, O., and Arcaro, A. (2007). Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia 21, 1921-1930.
19. Flanigan, S. A., Pitts, T. M., Eckhardt, S. G., Tentler, J. J., Tan, A. C., Thorburn, A., et al. (2010). The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models. Clin. Cancer Res. 16, 5436-5446.
20. Gallagher, E. J., and LeRoith, D. (2010). The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol. Metab. 21, 610-618.
21. Garcia-Echeverria, C., Pearson, M. A., Marti, A., Meyer, T., Mestan, J., Zimmermann, J., et al. (2004). In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5, 231-239.
22. Giovannucci, E., Pollak, M. N., Platz, E. A., Willett, W. C., Stampfer, M. J., Majeed, N., et al. (2000). A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol. Biomarkers Prev. 9, 345-349.
23. Goetsch, L., Gonzalez, A., Leger, O., Beck, A., Pauwels, P. J., Haeuw, J. F., et al. (2005). A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int. J. Cancer 113, 316-328.
24. Gong, Y., Yao, E., Shen, R., Goel, A., Arcila, M., Teruya-Feldstein, J., et al. (2009). High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS ONE 4:e7273. doi: 10.1371/journal.pone.0007273
25. Gualberto, A. (2010). Figitumumab (CP-751,871) for cancer therapy. Expert Opin. Biol. Ther. 10, 575-585.
26. Guerreiro, A. S., Boller, D., Doepfner, K. T., and Arcaro, A. (2006a). IGF-IR: potential role in antitumor agents. Drug News Perspect. 19, 261-272.
27. Guerreiro, A. S., Boller, D., Shalaby, T., Grotzer, M. A., and Arcaro, A. (2006b). Protein kinase B modulates the sensitivity of human neuroblastoma cells to insulin-like growth factor receptor inhibition. Int. J. Cancer 119, 2527-2538.
28. Haluska, P., Shaw, H. M., Batzel, G. N., Yin, D., Molina, J. R., Molife, L. R., et al. (2007). Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin. Cancer Res. 13, 5834-5840.
29. Harman, S. M., Metter, E. J., Blackman, M. R., Landis, P. K., and Carter, H. B. (2000). Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J. Clin. Endocrinol. Metab. 85, 4258-4265.
30. Kaaks, R., Toniolo, P., Akhmedkhanov, A., Lukanova, A., Biessy, C., Dechaud, H., et al. (2000). Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J. Natl. Cancer Inst. 92, 1592-1600.
31. Kaleko, M., Rutter, W. J., and Miller, A. D. (1990). Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol. Cell. Biol. 10, 464-473.
32. Kaulfuss, S., Burfeind, P., Gaedcke, J., and Scharf, J. G. (2009). Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Mol. Cancer Ther. 8, 821-833.
33. Khandwala, H. M., Mccutcheon, I. E., Flyvbjerg, A., and Friend, K. E. (2000). The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev. 21, 215-244.
34. Kindler, H. L., Richards, D. A., Garbo, L. E., Garon, E. B., Stephenson, J. J. Jr., Rocha-Lima, C. M., et al. (2012). A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann. Oncol. 23, 2834-2842.
35. King, E. R., and Wong, K. K. (2012). Insulin-like growth factor: current concepts and new developments in cancer therapy. Recent Pat. Anticancer Drug Discov. 7, 14-30.
36. Kolb, E. A., Gorlick, R., Lock, R., Carol, H., Morton, C. L., Keir, S. T., et al. (2011). Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr. Blood Cancer 56, 595-603.
37. Kolb, E. A., Kamara, D., Zhang, W., Lin, J., Hingorani, P., Baker, L., et al. (2010). R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr. Blood Cancer 55, 67-75.
38. Kurzrock, R., Patnaik, A., Aisner, J., Warren, T., Leong, S., Benjamin, R., et al. (2010). A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin. Cancer Res. 16, 2458-2465.
39. Lacy, M. Q., Alsina, M., Fonseca, R., Paccagnella, M. L., Melvin, C. L., Yin, D., et al. (2008). Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J. Clin. Oncol. 26, 3196-3203.
40. Litzenburger, B. C., Creighton, C. J., Tsimelzon, A., Chan, B. T., Hilsenbeck, S. G., Wang, T., et al. (2011). High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin. Cancer Res. 17, 2314-2327.
41. Ma, J., Pollak, M. N., Giovannucci, E., Chan, J. M., Tao, Y., Hennekens, C. H., et al. (1999). Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl. Cancer Inst. 91, 620-625.
42. Major, J. M., Laughlin, G. A., Kritz-Silverstein, D., Wingard, D. L., and Barrett-Connor, E. (2010). Insulin-like growth factor-I and cancer mortality in older men. J. Clin. Endocrinol. Metab. 95, 1054-1059.
43. Mitsiades, C. S., Mitsiades, N. S., Mcmullan, C. J., Poulaki, V., Shringarpure, R., Akiyama, M., et al. (2004). Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5, 221-230.
44. Molife, L. R., Fong, P. C., Paccagnella, L., Reid, A. H., Shaw, H. M., Vidal, L., et al. (2010). The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br. J. Cancer 103, 332-339.
45. Mulvihill, M. J., Cooke, A., Rosenfeld-Franklin, M., Buck, E., Foreman, K., Landfair, D., et al. (2009). Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med. Chem. 1, 1153-1171.
46. Naing, A., Lorusso, P., Fu, S., Hong, D. S., Anderson, P., Benjamin, R. S., et al. (2012). Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin. Cancer Res. 18, 2625-2631.
47. Olmos, D., Postel-Vinay, S., Molife, L. R., Okuno, S. H., Schuetze, S. M., Paccagnella, M. L., et al. (2010). Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751, 871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol. 11, 129-135.
48. Palmqvist, R., Hallmans, G., Rinaldi, S., Biessy, C., Stenling, R., Riboli, E., et al. (2002). Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut 50, 642-646.
49. Pandini, G., Frasca, F., Mineo, R., Sciacca, L., Vigneri, R., and Belfiore, A. (2002). Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J. Biol. Chem. 277, 39684-39695.
50. Pappo, A. S., Patel, S. R., Crowley, J., Reinke, D. K., Kuenkele, K. P., Chawla, S. P., et al. (2011). R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J. Clin. Oncol. 29, 4541-4547.
51. Pitts, T. M., Tan, A. C., Kulikowski, G. N., Tentler, J. J., Brown, A. M., Flanigan, S. A., et al. (2010). Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clin. Cancer Res. 16, 3193-3204.
52. Pollak, M. (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 8, 915-928.
53. Pollak, M. N., Schernhammer, E. S., and Hankinson, S. E. (2004). Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4, 505-518.
54. Quek, R., Wang, Q., Morgan, J. A., Shapiro, G. I., Butrynski, J. E., Ramaiya, N., et al. (2011). Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin. Cancer Res. 17, 871-879.
55. Ramalingam, S. S., Spigel, D. R., Chen, D., Steins, M. B., Engelman, J. A., Schneider, C. P., et al. (2011). Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 29, 4574-4580.
56. Reidy, D. L., Vakiani, E., Fakih, M. G., Saif, M. W., Hecht, J. R., Goodman-Davis, N., et al. (2010). Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J. Clin. Oncol. 28, 4240-4246.
57. Reidy-Lagunes, D. L., Vakiani, E., Segal, M. F., Hollywood, E. M., Tang, L. H., Solit, D. B., et al. (2012). A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer 118, 4795-4800.
58. Renehan, A. G., Zwahlen, M., Minder, C., O'Dwyer, S. T., Shalet, S. M., and Egger, M. (2004). Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363, 1346-1353.
59. Rinaldi, S., Cleveland, R., Norat, T., Biessy, C., Rohrmann, S., Linseisen, J., et al. (2010). Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int. J. Cancer 126, 1702-1715.
60. Rowinsky, E. K., Youssoufian, H., Tonra, J. R., Solomon, P., Burtrum, D., and Ludwig, D. L. (2007). IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin. Cancer Res. 13, 5549s-5555s.
61. Sachdev, D., Hartell, J. S., Lee, A. V., Zhang, X., and Yee, D. (2004). A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J. Biol. Chem. 279, 5017-5024.
62. Scartozzi, M., Bianconi, M., Maccaroni, E., Giampieri, R., Berardi, R., and Cascinu, S. (2010). Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr. Opin. Mol. Ther. 12, 361-371.
63. Schmitz, S., Kaminsky-Forrett, M. C., Henry, S., Zanetta, S., Geoffrois, L., Bompas, E., et al. (2012). Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). Ann. Oncol. 23, 2153-2161.
64. Scotlandi, K., Avnet, S., Benini, S., Manara, M. C., Serra, M., Cerisano, V., et al. (2002). Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int. J. Cancer 101, 11-16.
65. Scotlandi, K., Manara, M. C., Nicoletti, G., Lollini, P. L., Lukas, S., Benini, S., et al. (2005). Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 65, 3868-3876.
66. Sell, C., Dumenil, G., Deveaud, C., Miura, M., Coppola, D., Deangelis, T., et al. (1994). Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol. Cell. Biol. 14, 3604-3612.
67. Stattin, P., Bylund, A., Rinaldi, S., Biessy, C., Dechaud, H., Stenman, U. H., et al. (2000). Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J. Natl. Cancer Inst. 92, 1910-1917.
68. Tanno, B., Mancini, C., Vitali, R., Mancuso, M., Mcdowell, H. P., Dominici, C., et al. (2006). Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo. Clin. Cancer Res. 12, 6772-6780.
69. Tap, W. D., Demetri, G., Barnette, P., Desai, J., Kavan, P., Tozer, R., et al. (2012). Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J. Clin. Oncol. 30, 1849-1856.
70. Tazzari, P. L., Tabellini, G., Bortul, R., Papa, V., Evangelisti, C., Grafone, T., et al. (2007). The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia 21, 886-896.
71. Tolcher, A. W., Sarantopoulos, J., Patnaik, A., Papadopoulos, K., Lin, C. C., Rodon, J., et al. (2009). Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J. Clin. Oncol. 27, 5800-5807.
72. Urbanska, K., Trojanek, J., Del Valle, L., Eldeen, M. B., Hofmann, F., Garcia-Echeverria, C., et al. (2007). Inhibition of IGF-I receptor in anchorage-independence attenuates GSK-3beta constitutive phosphorylation and compromises growth and survival of medulloblastoma cell lines. Oncogene 26, 2308-2317.
73. Wan, X., Harkavy, B., Shen, N., Grohar, P., and Helman, L. J. (2007). Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26, 1932-1940.
74. Wang, Y., Hailey, J., Williams, D., Lipari, P., Malkowski, M., Wang, X., et al. (2005). Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol. Cancer Ther. 4, 1214-1221.
75. Warshamana-Greene, G. S., Litz, J., Buchdunger, E., Garcia-Echeverria, C., Hofmann, F., and Krystal, G. W. (2005). The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin. Cancer Res. 11, 1563-1571.
76. Wittman, M. D., Carboni, J. M., Yang, Z., Lee, F. Y., Antman, M., Attar, R., et al. (2009). Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development. J. Med. Chem. 52, 7360-7363.
77. Wojtalla, A., Salm, F., Christiansen, D. G., Cremona, T., Cwiek, P., Shalaby, T., et al. (2012). Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma. PLoS ONE 7:e47109. doi: 10.1371/journal.pone.0047109
78. Wolk, A., Mantzoros, C. S., Andersson, S. O., Bergstrom, R., Signorello, L. B., Lagiou, P., et al. (1998). Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl. Cancer Inst. 90, 911-915.
79. Zeng, X., Zhang, H., Oh, A., Zhang, Y., and Yee, D. (2012). Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor. Breast Cancer Res. Treat. 133, 117-126.